Amo Pharma has reported positive results from its Phase II trial evaluating the safety and efficacy of AMO-02 (tideglusib), a GSK3β inhibitor, for the treatment of patients with autism spectrum disorder (ASD). In the randomised, double-blinded study, 83 adolescents with ASD received AMO-02 or placebo over 12 weeks. The drug was found to be generally safe and well tolerated. Patients receiving AMO-02 recorded improvements over placebo in measures of social withdrawal (ABC-Social) and repetitive behaviours (RBS-R), as well as daily living skills (Vineland), memory (NEPSY) and sleep quality (CSHQ).
Chief Medical Officer, Joe Horrigan, said that treatment with AMO-02 has the potential to offer meaningful, multi-symptom benefit in ASD.
Amo Pharma is also advancing development of AMO-04, a glutamate modulator, for the treatment of Rett syndrome, for which it has entered into a development and licensing agreement with Numedicus Limited
https://globalgenes.org/raredaily/a...-study-of-amo-02-in-autism-spectrum-disorder/
https://www.drugdevelopment-technology.com/news/amo-pharma-reports-positive-results-from-tide-trial/
https://www.amo-pharma.com/index.htm
- Forums
- ASX - By Stock
- Trump, Big Pharma and orphan drugs
Amo Pharma has reported positive results from its Phase II trial...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.60 |
Change
0.000(0.00%) |
Mkt cap ! $1.993B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9814 | $17.29 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.50 | 1650 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 644 | 16.750 |
2 | 2317 | 16.380 |
1 | 113 | 16.200 |
1 | 95 | 16.100 |
1 | 2309 | 16.000 |
Price($) | Vol. | No. |
---|---|---|
15.000 | 5000 | 1 |
15.520 | 247 | 3 |
15.550 | 674 | 2 |
15.600 | 522 | 2 |
15.700 | 30 | 1 |
Last trade - 09.46am 15/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online